Chemotherapy and Internal Radiation in Treating Patients With Colorectal Cancer That Has Spread to the Liver
NCT ID: NCT00408551
Last Updated: 2013-12-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
20 participants
INTERVENTIONAL
2005-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This phase II trial is studying how well giving chemotherapy together with internal radiation works in treating patients with colorectal cancer that has spread to the liver.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* Evaluate the tumor response, as measured by total tumor mass, carcinoembryonic antigen (CEA) level, measurable tumor volume by CT scan, and metabolic response by positron emission tomography (PET) scan, in patients with colorectal cancer metastatic to the liver undergoing chemotherapy and selective internal radiation therapy (SIRT) comprising yttrium Y 90 resin microspheres.
* Evaluate the hepatic toxicity of this regimen, as measured by ALT, alkaline phosphatase, and bilirubin levels, in these patients.
Secondary
* Evaluate the therapeutic efficacy of this regimen, using time to in-liver disease progression as an end point, in these patients.
* Evaluate the therapeutic efficacy of this regimen, using down-staging to resectability as an end point, in these patients.
OUTLINE: This is a multicenter study.
Patients receive 1 of the following chemotherapy regimens:
* FOLFOX6: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continously over 46 hours beginning on day 1.
* FOLFIRI: Patients receive irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1.
* FUDR: Patients receive floxuridine IV continuously on days 1-14. In all chemotherapy regimens, treatment repeats every 2 weeks for up to 8 courses in the absence of disease progression or unacceptable toxicity.
Patients also undergo selective internal radiation therapy (SIRT) comprising yttrium Y 90 resin microspheres on day 2 of chemotherapy course 1 (for patients receiving FOLFOX6 or FOLFIRI chemotherapy regimens) or on day 1, 2, 3, 4, or 5 of course 1 (for patients receiving FUDR chemotherapy regimen). SIRT may repeat in week 10 or 12.
In week 18, patients may undergo surgery if down-staging has occurred or they may receive more chemotherapy.
After completion of study therapy, patients are followed every 3 months for up to 2 years.
PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FOLFOX6
Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continously over 46 hours beginning on day 1.
fluorouracil
Given IV
leucovorin calcium
Given IV
oxaliplatin
Given IV
FOLFIRI
Patients receive irinotecan hydrochloride IV over 1 hour and leucovorin calcium IV over 2 hours on day 1. Patients also receive fluorouracil IV continuously over 46 hours beginning on day 1.
fluorouracil
Given IV
irinotecan hydrochloride
Given IV
leucovorin calcium
Given IV
FUDR
Patients receive floxuridine IV continuously on days 1-14.
floxuridine
Given IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
floxuridine
Given IV
fluorouracil
Given IV
irinotecan hydrochloride
Given IV
leucovorin calcium
Given IV
oxaliplatin
Given IV
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically or cytologically confirmed colorectal cancer\* meeting 1 of the following criteria:
* Metachronous metastasis after resection of Dukes A-C (i.e., stage I-III) primary colon cancer with or without adjuvant chemotherapy
* Metachronous metastasis after resection of primary rectal cancer with neoadjuvant or adjuvant chemotherapy
* Synchronous metastatic liver disease with symptomatic or asymptomatic primary colorectal cancer NOTE: \*If the patient has a second malignancy with liver metastasis potential, histologic or cytologic confirmation of the liver lesions may be performed as clinically indicated
* Liver-only or liver-predominant disease with any of the following:
* Unresected primary disease
* Limited bone or lung disease
* Potentially resectable nodal disease
* Anastomotic disease
* No active CNS metastasis or diffuse peritoneal metastasis
* No hepatic metastases from a second malignancy
* No predominant extrahepatic disease
PATIENT CHARACTERISTICS:
* ECOG performance status 0-2
* Life expectancy \> 3 months
* Platelet count ≥ 100,000/mm\^3
* Hemoglobin ≥ 9 g/dL
* WBC ≥ 1,500/mm\^3
* Creatinine ≤ 2 mg/dL
* Bilirubin ≤ 2 mg/dL (without extrahepatic biliary obstruction)
* Albumin \> 2 g/dL
* INR \< 1.5 (without anticoagulation)
* Not pregnant or nursing
* Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
* See Disease Characteristics
* No prior external-beam radiotherapy to the liver
* Concurrent targeted therapy agents (e.g., bevacizumab or cetuximab) allowed
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Goshen Health System
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Center for Cancer Care at Goshen General Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kenneth L. Pennington, MD
Role: STUDY_CHAIR
Goshen Health System
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Cancer Care at Goshen General Hospital
Goshen, Indiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Clinical Trials Office - Center for Cancer Care at Goshen Gene
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CCCGHS-CHEMO-SIRT
Identifier Type: -
Identifier Source: secondary_id
CDR0000515900
Identifier Type: -
Identifier Source: org_study_id